Cubist Systematic Strategies’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Cubist Systematic Strategies’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-39,187	Closed	-$116K	–	4671
2022 Q1	$116K	Buy	39,187 +26,661	+213%	+$100K	﹤0.01%	3202
2021 Q4	$56K	Buy	+12,526	New	+$59.4K	﹤0.01%	3301
2021 Q3	–	Sell	-36,486	Closed	-$249K	–	3251
2021 Q2	$249K	Buy	36,486 +6,747	+23%	+$54.5K	﹤0.01%	2440
2021 Q1	$210K	Sell	29,739 -8,862	-23%	-$63.8K	﹤0.01%	2442
2020 Q4	$242K	Sell	38,601 -16,346	-30%	-$96.2K	﹤0.01%	2142
2020 Q3	$297K	Buy	+54,947	New	+$272K	﹤0.01%	1991
2019 Q2	–	Sell	-25,927	Closed	-$139K	–	2626
2019 Q1	$139K	Buy	25,927 +2,059	+9%	+$13.3K	﹤0.01%	1923
2018 Q4	$122K	Buy	+23,868	New	+$181K	0.01%	1718
2018 Q2	–	Sell	-11,274	Closed	-$147K	–	2119
2018 Q1	$147K	Buy	+11,274	New	+$168K	0.01%	1507
2016 Q4	–	Sell	-822	Closed	-$11K	–	1932
2016 Q3	$11K	Sell	822 -3,811	-82%	-$50.5K	﹤0.01%	1638
2016 Q2	$64K	Buy	+4,633	New	+$68.2K	﹤0.01%	1563

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Cubist Systematic Strategies's PRTK Position: Q2 2022 in Review

Cubist Systematic Strategies sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 39,187 shares — an estimated $116K sold.

Cubist Systematic Strategies first reported a position in PRTK in Q2 2016 and held it in 11 quarters. The position peaked at $297K in Q3 2020. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

Cubist Systematic Strategies reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 39,187 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $116K.
Cubist Systematic Strategies first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 11 quarters.
Cubist Systematic Strategies's Paratek Pharmaceuticals, Inc. position peaked at $297K in Q3 2020.
84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on Cubist Systematic Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.